{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-22-019454","form_type":"8-K","ticker":"PGEN","cik":"0001356090","company_name":"PRECIGEN, INC.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.309012+00:00","generated_at":"2026-06-22T00:50:05.161691+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Precigen Q3 net loss $7.6M; cash $153.8M; retired $144M convertible notes","bullets":["Net loss from continuing ops $7.6M ($0.04/sh) vs $26.3M loss; total revenues up $13.4M (>200%) YoY.","Cash, equivalents, short-term investments and restricted cash totaled $153.8M as of Sep 30, 2022.","Retired $144M of $200M convertible notes due July 2023 at a discount; realized $5.4M savings.","Clinical: Phase 1 enrollment complete for PRGN-2012 in RRP; virtual R&D event Jan 2023; ASH presentations.","Phase 1b expansion for PRGN-3006 at Mayo Clinic; first patient dosed; FDA clearance for repeat dosing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-22-019454","json":"https://secwatch.observer/filing/0000950103-22-019454.json","markdown":"https://secwatch.observer/filing/0000950103-22-019454.md","text":"https://secwatch.observer/filing/0000950103-22-019454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322019454/0000950103-22-019454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322019454/dp184115_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:50:05.161691+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a60b8e4519a42caa44ce0c2be45e235bebc3e1f2","claim":"PRECIGEN, INC. reported financial results for third quarter 2022.","evidence_excerpt":"precigen reports third quarter 2022 financial results and progress of clinical programs","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356090/000095010322019454/0000950103-22-019454-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}